Salk Institute for Biological Studies

San Diego, CA, United States

Salk Institute for Biological Studies

San Diego, CA, United States

The Salk Institute for Biological Studies is an independent, non-profit, scientific research institute located in La Jolla, California. It was founded in 1960 by Jonas Salk, the developer of the polio vaccine; among the founding consultants were Jacob Bronowski and Francis Crick. Building did not start until spring of 1962. The institute consistently ranks among the top institutions in the US in terms of research output and quality in the life science. In 2004, the Times Higher Education Supplement ranked Salk as the world's top biomedicine research institute, and in 2009 it was ranked number one globally by ScienceWatch in the neuroscience and behavior areas.The institute employs 850 researchers in 60 research groups and focuses its research in three areas: Molecular Biology and Genetics; Neuroscience; and Plant Biology. Research topics include cancer, diabetes, birth defects, Alzheimer's disease, Parkinson's disease, AIDS, and the neurobiology of American Sign Language. The March of Dimes provided the initial funding and continues to support the institute. Current research is funded by a variety of organizations, such as the NIH, the HHMI and private organizations such as Paris-based Ipsen and the Waitt Family Foundation. In addition, the internally administered Innovation Grants Program encourages cutting-edge high-risk research. The institute appointed genome biologist Eric Lander and stem cell biologist Irving Weissman as non-resident fellows in November 2009.The campus was designed by Louis Kahn. Salk had sought to make a beautiful campus in order to draw the best researchers in the world. Salk and Kahn having both descended from Russian Jewish parents that had immigrated to the United States had a deeper connection than just mere partners on an architectural project. The results of their connection is seen in the design that resulted from their collaboration. The original buildings of the Salk Institute were designated as a historical landmark in 1991. The entire 27-acre site was deemed eligible by the California Historical Resources Commission in 2006 for listing on the National Register of Historic Places. Wikipedia.


Time filter

Source Type

Patent
Salk Institute for Biological Studies and Kolltan Pharmaceuticals | Date: 2016-09-20

The present disclosure provides methods for modulating the interaction between a TAM ligand and a lipid membrane containing phosphatidyl serine (PtdSer). In one example, such methods use a TAM receptor agonist having a PtdSer-containing lipid bilayer membrane with Gas6 and/or Protein S bound to the membrane to activate signaling from one or more TAM receptors and treat an autoimmune disease. In another example, methods are provided for treating a subject with a pathological condition characterized by overactivation of TAM signaling and/or reduction in Type I IFN response, such as infection by an enveloped virus, by use of agents that decrease the interaction between a TAM ligand and PtdSer. Also provided are methods for classifying a virus as susceptible to anti-TAM therapy. Methods of identifying an agent that blocks virus infectivity are also provided.


Patent
Salk Institute for Biological Studies | Date: 2017-02-01

The invention features compositions comprising in vitro generated beta cells capable of glucose-stimulated insulin secretion, methods of inducing beta cell maturation from embryonic or induced pluripotent stem cell-derived beta-like cells, and methods of using in vitro generated beta cells for treatment of type 1 diabetes, type 2 diabetes, or a related disorder.


Patent
Salk Institute for Biological Studies | Date: 2017-01-18

Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.


Patent
Salk Institute for Biological Studies | Date: 2016-12-02

Disclosed is a polypeptide that includes amino acids 183-222 of CRIF, wherein the polypeptide does not include the full length CRIF1 amino acid sequence. Also disclosed is a nucleic acid molecule encoding this polypeptide, vectors including this nucleic acid molecule, and host cells transformed with these vectors. In some embodiments, methods are disclosed for treating a subject with cancer, comprising administering to the subject a therapeutically effective amount of an inhibitor of CDK12/CRIF1 interaction, thereby treating the cancer in the subject. In specific non-limiting examples, these methods can utilize CRIF1 polypeptides, nucleic acids encoding these polypeptides, and vectors including these nucleic acids.


Patent
Salk Institute for Biological Studies and Celldex Therapeutics, Inc. | Date: 2017-06-28

The invention provides a TAM receptor agonist for use in a method of treating an autoimmune disease in a subject, wherein the TAM receptor agonist comprises a phosphatidyl serine (PtdSer) -containing lipid bilayer membrane with Gas6 and/or Protein S bound to the membrane, wherein signaling from one or more TAM receptors is activated. The invention further provides a composition comprising a PtdSer-containing membrane having a Gas6 and/or Protein S protein bound to said membrane. Further provided is a method for classifying a virus as susceptible to anti-TAM therapy and a method of identifying an agent that blocks virus infectivity.


Patent
Salk Institute for Biological Studies | Date: 2017-01-13

Provided herein are self-renewable nephron progenitor cell (srNPC) and methods for making and using.


Patent
Salk Institute for Biological Studies | Date: 2017-03-24

Recombinant adenoviruses that selectively replicate in E2F deregulated tumor cells are described. The recombinant adenoviruses have a genome encoding a modified E1A protein, a modified or deleted E4orf1 protein, a modified or deleted E4orf6/7 protein, or any combination thereof, such that the recombinant adenoviruses exhibit replication defects in normal cells compared to tumor cells. In some instances, the recombinant adenovirus genomes encode additional modifications that target the recombinant adenoviruses to specific cell types, detarget the viruses from the liver, inhibit viral replication in the liver, and/or evade pre-existing neutralizing antibodies.


Patent
Salk Institute for Biological Studies | Date: 2017-04-07

Provided herein are deuterated compounds and compositions useful in increasing PPAR activity. The compounds and compositions provided herein are useful for the treatment of PPAR related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).


Patent
Salk Institute for Biological Studies | Date: 2017-08-02

Recombinant adenoviruses that selectively replicate in E2F deregulated tumor cells are described. The recombinant adenoviruses have a genome encoding a modified El A protein, a modified or deleted E4orf 1 protein, a modified or deleted E4orf6/7 protein, or any combination thereof, such that the recombinant adenoviruses exhibit replication defects in normal cells compared to tumor cells. In some instances, the recombinant adenovirus genomes encode additional modifications that target the recombinant adenoviruses to specific cell types, detarget the viruses from the liver, inhibit viral replication in the liver, and/or evade pre-existing neutralizing antibodies.


Allen N.J.,Salk Institute for Biological Studies
Annual review of cell and developmental biology | Year: 2014

Astrocytes regulate multiple aspects of neuronal and synaptic function from development through to adulthood. Instead of addressing each function independently, this review provides a comprehensive overview of the different ways astrocytes modulate neuronal synaptic function throughout life, with a particular focus on recent findings in each area. It includes the emerging functions of astrocytes, such as a role in synapse formation, as well as more established roles, including the uptake and recycling of neurotransmitters. This broad approach covers the many ways astrocytes and neurons constantly interact to maintain the correct functioning of the brain. It is important to consider all of these diverse functions of astrocytes when investigating how astrocyte-neuron interactions regulate synaptic behavior to appreciate the complexity of these ongoing interactions.

Loading Salk Institute for Biological Studies collaborators
Loading Salk Institute for Biological Studies collaborators